Dietary soy protein selectively reduces renal prostanoids and cyclooxygenases in polycystic kidney disease

Experimental Biology and Medicine

Volumn 234, Issue 7, 2009, Pages 737-743

  Peng, Claudia Yu Chen ^a   Sankaran, Deepa ^a   Ogborn, Malcolm R ^a,b   Aukema, Harold M ^a,b  

^a UNIVERSITY OF MANITOBA   (Canada)

^b MANITOBA INSTITUTE OF CHILD HEALTH   (Canada)

Author keywords

Cyclooxygenase; Polycystic kidney disease; Prostaglandin; Soy protein; Thromboxane

Indexed keywords

6 OXOPROSTAGLANDIN F1 ALPHA; CASEIN; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYTOSOLIC PHOSPHOLIPASE A2; MESSENGER RNA; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE; PROSTANOID; SOYBEAN PROTEIN; THROMBOXANE B2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DIET; DISEASE COURSE; DRUG EFFECT; ENZYME ACTIVITY; IN VITRO STUDY; KIDNEY; KIDNEY POLYCYSTIC DISEASE; MALE; NONHUMAN; PROTEIN INTAKE; RAT; STEADY STATE;

6-KETOPROSTAGLANDIN F1 ALPHA; ANIMALS; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DINOPROSTONE; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; KIDNEY; MALE; PHOSPHOLIPASES A2; POLYCYSTIC KIDNEY DISEASES; PROSTAGLANDINS; RATS; RATS, MUTANT STRAINS; RNA, MESSENGER; SOYBEAN PROTEINS; THROMBOXANE B2;

ANIMALIA; RATTUS;

EID: 67650215135     PISSN: 15353702     EISSN: 15353699     Source Type: Journal    
DOI: 10.3181/0811-RM-315     Document Type: Article

References (44)

1. Imig JD. Eicosanoids and renal vascular function in diseases. Clin Sci (Lond) 111:21-34, 2006.
2. Nasrallah R, Hebert RL. Prostacyclin signaling in the kidney: implications for health and disease. Am J Physiol Renal Physiol 289:F235-F246, 2005.
3. Hao CM, Breyer MD. Physiological regulation of prostaglandins in the kidney. Annu Rev Physiol 70:357-377, 2008.
4. Klahr S, Purkerson ML. Eicosanoids: role in experimental renal disease. Adv Exp Med Biol 259:249-274, 1989.
5. Claria J, Arroyo V. Prostaglandins and other cyclooxygenase-dependent arachidonic acid metabolites and the kidney in liver disease. Prostaglandins Other Lipid Mediat 72:19-33, 2003.
6. Breyer MD, Badr KF. Arachidonic acid metabolites and the kidney. In: Brenner BM, Ed. Brenner and Rector's The Kidney (5th ed.). Toronto: W.B. Saunders Co, pp754-788, 1996.
7. Azadbakht L, Atabak S, Esmaillzadeh A. Soy protein intake, cardiorenal indices, and C-reactive protein in type 2 diabetes with nephropathy: a longitudinal randomized clinical trial. Diabetes Care 31:648-654, 2008.
8. Azadbakht L, Shakerhosseini R, Atabak S, Jamshidian M, Mehrabi Y, Esmaill-Zadeh A. Beneficiary effect of dietary soy protein on lowering plasma levels of lipid and improving kidney function in type II diabetes with nephropathy. Eur J Clin Nutr 57:1292-1294, 2003.
9. Aukema HM, Housini I, Rawling JM. Dietary soy protein effects on inherited polycystic kidney disease are influenced by gender and protein level. J Am Soc Nephrol 10:300-308, 1999.
10. Hwang SY, Taylor CG, Zahradka P, Bankovic-Calic N, Ogborn MR, Aukema HM. Dietary soy protein reduces early renal disease progression and alters prostanoid production in obese fa/fa zucker rats. J Nutr Biochem 19:255-262, 2008.
11. Ogborn MR, Bankovic-Calic N, Shoesmith C, Buist R, Peeling J. Soy protein modification of rat polycystic kidney disease. Am J Physiol 274:F541-F549, 1998.
12. Tomobe K, Philbrick DJ, Ogborn MR, Takahashi H, Holub BJ. Effect of dietary soy protein and genistein on disease progression in mice with polycystic kidney disease. Am J Kidney Dis 31:55-61, 1998.
13. Teixeira SR, Tappenden KA, Erdman JW Jr. Altering dietary protein type and quantity reduces urinary albumin excretion without affecting plasma glucose concentrations in BKS.cg-m +Lepr db/+Lepr db (db/db) mice. J Nutr 133:673-678, 2003.
14. Williams AJ, Baker F, Walls J. Effect of varying quantity and quality of dietary protein intake in experimental renal disease in rats. Nephron 46:83-90, 1987.
15. Maddox DA, Alavi FK, Silbernick EM, Zawada ET. Protective effects of a soy diet in preventing obesity-linked renal disease. Kidney Int 61:96-104, 2002.
16. Kontessis P, Jones S, Dodds R, Trevisan R, Nosadini R, Fioretto P, Borsato M, Sacerdoti D, Viberti G. Renal, metabolic and hormonal responses to ingestion of animal and vegetable proteins. Kidney Int 38:136-144, 1990.
17. Kitazato H, Fujita H, Shimotomai T, Kagaya E, Narita T, Kakei M, Ito S. Effects of chronic intake of vegetable protein added to animal or fish protein on renal hemodynamics. Nephron 90:31-36, 2002.
18. Dhaene M, Sabot JP, Philippart Y, Doutrelepont JM, Vanherweghem JL. Effects of acute protein loads of different sources on glomerular filtration rate. Kidney Int Suppl 22:S25-S28, 1987.
19. Blume C, Heise G, Muhlfeld A, Bach D, Schror K, Gerhardz CD, Grabensee B, Heering P. Effect of flosulide, a selective cyclooxygenase 2 inhibitor, on passive heymann nephritis in the rat. Kidney Int 56:1770-1778, 1999.
20. Cheng HF, Wang CJ, Moeckel GW, Zhang MZ, McKanna JA, Harris RC. Cyclooxygenase-2 inhibitor blocks expression of mediators of renal injury in a model of diabetes and hypertension. Kidney Int 62:929-939, 2002.
21. Dey A, Maric C, Kaesemeyer WH, Zaharis CZ, Stewart J, Pollock JS, Imig JD. Rofecoxib decreases renal injury in obese zucker rats. Clin Sci (Lond) 107:561-570, 2004.
22. Fujihara CK, Antunes GR, Mattar AL, Andreoli N, Malheiros DM, Noronha IL, Zatz R. Cyclooxygenase-2 (COX-2) inhibition limits abnormal COX-2 expression and progressive injury in the remnant kidney. Kidney Int 64:2172-2181, 2003.
23. Komers R, Lindsley JN, Oyama TT, Schutzer WE, Reed JF, Mader SL, Anderson S. Immunohistochemical and functional correlations of renal cyclooxygenase-2 in experimental diabetes. J Clin Invest 107:889-898, 2001.
24. Rodriguez F, Llinas MT, Gonzalez JD, Rivera J, Salazar FJ. Renal changes induced by a cyclooxygenase-2 inhibitor during normal and low sodium intake. Hypertension 36:276-281, 2000.
25. Sanchez PL, Salgado LM, Ferreri NR, Escalante B. Effect of cyclooxygenase-2 inhibition on renal function after renal ablation. Hypertension 34:848-853, 1999.
26. Zoja C, Benigni A, Noris M, Corna D, Casiraghi F, Pagnoncelli M, Rottoli D, Abbate M, Remuzzi G. Mycophenolate mofetil combined with a cyclooxygenase-2 inhibitor ameliorates murine lupus nephritis. Kidney Int 60:653-663, 2001.
27. Whelton A. Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications. Am J Med 106:13S-24S, 1999.
28. Harris RC. COX-2 and the kidney. J Cardiovasc Pharmacol 47 Suppl 1:S37-S42, 2006.
29. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, Lines C, Riddell R, Morton D, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 352:1092-1102, 2005.
30. Chaiamnuay S, Allison JJ, Curtis JR. Risks versus benefits of cyclooxygenase-2-selective nonsteroidal antiinflammatory drugs. Am J Health Syst Pharm 63:1837-1851, 2006.
31. 2 and cyclooxygenases in polycystic kidney disease. FASEB J 17:298-300, 2003.
32. Sankaran D, Bankovic-Calic N, Ogborn MR, Crow G, Aukema HM. Selective COX-2 inhibition markedly slows disease progression and attenuates altered prostanoid production in Han:SPRD-cy rats with inherited kidney disease. Am J Physiol Renal Physiol 293:F821-F830, 2007.
33. Warford-Woolgar L, Peng CY, Shuhyta J, Wakefield A, Sankaran D, Ogborn M, Aukema HM. Selectivity of cyclooxygenase isoform activity and prostanoid production in normal and diseased Han:SPRDcy rat kidneys. Am J Physiol Renal Physiol 290:F897-904, 2006.
34. Cahill LE, Peng CY, Bankovic-Calic N, Sankaran D, Ogborn MR, Aukema HM. Dietary soya protein during pregnancy and lactation in rats with hereditary kidney disease attenuates disease progression in offspring. Br J Nutr 97:77-84, 2007.
35. Cowley BD Jr, Gudapaty S, Kraybill AL, Barash BD, Harding MA, Calvet JP, Gattone VH 2nd. Autosomal-dominant polycystic kidney disease in the rat. Kidney Int 43:522-534, 1993.
36. Schafer K, Gretz N, Bader M, Oberbaumer I, Eckardt KU, Kriz W, Bachmann S. Characterization of the Han:SPRD rat model for hereditary polycystic kidney disease. Kidney Int 46:134-152, 1994.
37. Niwa T, Maeda K, Shibata M. Urinary prostaglandins and thromboxane in patients with chronic glomerulonephritis. Nephron 46:281-287, 1987.
38. Castellani S, Paniccia R, Di Serio C, La Cava G, Poggesi L, Fumagalli S, Gensini GF, Neri Serneri GG. Thromboxane inhibition improves renal perfusion and excretory function in severe congestive heart failure. J Am Coll Cardiol 42:133-139, 2003.
39. Yamashita W, Ito Y, Weiss MA, Ooi BS, Pollak VE. A thromboxane synthetase antagonist ameliorates progressive renal disease of dahl-S rats. Kidney Int 33:77-83, 1988.
40. Nakahama K, Morita I, Murota S. Effects of endogenously produced arachidonic acid metabolites on rat mesangial cell proliferation. Prostaglandins Leukot Essent Fatty Acids 51:177-182, 1994.
41. Matsell DG, Gaber LW, Malik KU. Cytokine stimulation of prostaglandin production inhibits the proliferation of serum-stimulated mesangial cells. Kidney Int 45:159-165, 1994.
42. Horiba N, Kumano E, Watanabe T, Shinkura H, Sugimoto T, Inoue M. Subtotal nephrectomy stimulates cyclooxygenase 2 expression and prostacyclin synthesis in the rat remnant kidney. Nephron 91:134-141, 2002.
43. Komers R, Zdychova J, Cahova M, Kazdova L, Lindsley JN, Anderson S. Renal cyclooxygenase-2 in obese zucker (fatty) rats. Kidney Int 67:2151-2158, 2005.
44. Wang JL, Cheng HF, Harris RC. Cyclooxygenase-2 inhibition decreases renin content and lowers blood pressure in a model of renovascular hypertension. Hypertension 34:96-101, 1999.